IMPORTANCE Peripartum cardiomyopathy (PPCM) disproportionately affects women of African ancestry, but well-powered studies to explore differences in severity of disease and clinical outcomes are lacking.
P eripartum cardiomyopathy (PPCM) is an often devastating form of maternal systolic heart failure that occurs toward the end of pregnancy or in the months after delivery in the absence of a clear cause or preexisting heart disease. [1] [2] [3] Previous research has suggested that PPCM is hormonal and vascular in origin. [4] [5] [6] In addition, recent work has revealed the frequent occurrence in women with PPCM of mutations in the large sarcomeric gene titin (TTN) (OMIM 188840), supporting a strong role for genetics in PPCM. 7 Consistent with a genetic contribution to PPCM, several studies [8] [9] [10] have also suggested that women of African ancestry are disproportionately affected by PPCM and face a worse prognosis. Overall, however, small sample sizes and limited access to medical records have limited the detailed understanding and the generalizability of clinical outcomes between African American and non-African American women. We leveraged the high prevalence of PPCM in the University of Pennsylvania Health System (UPHS), and particularly of women of African ancestry who had PPCM, to explore clinical characteristics at presentation and outcomes in a cohort of 220 women with PPCM, including 121 African American women, who are to our knowledge the largest such cohort to date.
Methods
We retrospectively identified all patients in the UPHS from January 1, 1986, through December 31, 2016, with a potential diagnosis of PPCM based on diagnostic codes (International Classification of Diseases, Ninth Revision codes 674.50-54) or echocardiographic results within 6 months of delivery and manually reviewed electronic medical records. Patients were included if they were diagnosed with PPCM or heart failure toward the end of pregnancy or in the several months after delivery, had echocardiographic documentation of systolic dysfunction (left ventricular ejection fraction [LVEF] <45% or fractional shortening <30%), and had no history of congenital heart disease, valvular disease predating PPCM, radiation or cardiotoxic chemotherapy, or other explanation for their heart failure (eFigure 1 in the Supplement). The University of Pennsylvania Institutional Review Board approved the study and determined that informed consent was not required. Continuous variables were assessed using the 2-tailed t test or Wilcoxon rank sum test. Categorical variables were compared with the χ 2 analysis or Fisher exact test. Survival curves used the Kaplan-Meier method. P < .05 (2-tailed) was considered to be statistically significant.
Results
A total of 491 women were identified as having PPCM. 
Key Points
Question What are the differences in presentation and outcomes between African American and non-African American women with peripartum cardiomyopathy?
Findings In this cohort study of African American women compared with non-African American women with peripartum cardiomyopathy, African American women were diagnosed with peripartum cardiomyopathy later in the postpartum period, presented with more severe disease, recovered less frequently, and took longer to recover compared with their non-African American counterparts.
Meaning African American women with peripartum cardiomyopathy have a different disease profile and trajectory compared with non-African American women; future studies are needed to explore potential genetic explanations for these differences and to investigate whether personalized therapeutic approaches could benefit African American women with peripartum cardiomyopathy differently. 
Discussion
To our knowledge, this retrospective review of 220 women represents the largest study of PPCM cases to date and in particular of African American women with PPCM. Previously wellestablished epidemiologic observations were recapitulated, including the relative advanced age of women, presentation largely in the first few weeks after delivery, and high prevalence of twin pregnancies and gestational hypertension.
2,12
Striking observations were made in racial differences. African American patients were diagnosed younger, consistent with prior reports, 10 and likely reflected a younger African
American obstetric population at the UPHS (mean age for African American women vs non-African American women, 23.2 vs 30.5 years). African American patients were diagnosed later post partum than non-African American patients (Figure 1 ), a finding not previously reported likely because of insufficient cohort sizes. African American patients were also more likely to present with an LVEF less than 30%. Late diagnosis and low 
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LVEF at presentation may reflect a delay in presentation, allowing disease to progress before receiving appropriate treatment, or may instead reflect a different pathophysiologic phenotype with later development of clinical heart failure in African American patients. African American patients had higher rates of chronic hypertension, a difference not seen in the general UPHS obstetrical population. However, rates of gestational hypertension were remarkably high in both groups, in keeping with the wellestablished strong association between pregnancy-related hypertension and PPCM. 2, 12 This observation suggests that pathophysiologic differences between PPCM in African American and non-African American patients are unlikely to be caused by a different burden of gestational hypertension. Despite their younger age at diagnosis, African American women with PPCM had worse outcomes than non-African American women. African American women were twice as likely to experience worsening of their LVEF after diagnosis, had significantly lower worst documented LVEF, and were twice as likely to fail to recover to an LVEF of 50% or higher. Furthermore, even among those who ultimately recovered, the time to recovery for African American patients was more than twice as long as that for non-African American patients ( Figure 2 ) despite a similar rate of treatment with β-blockers and angiotensin-converting enzyme inhibitors.
Together, these findings indicate that African American patients are affected with a pathophysiologically more severe form of PPCM or there are environmental factors that lead to more severe presentation and disease progression. Racial disparities in health care, socioeconomics, and prevalence of classic cardiovascular disease risk factors, such as obesity, have been widely studied and well established.
13,14 Although our study was unable to explore many of these socioeconomic variables, we assessed at least 1 surrogate of access to care, medication use, and did not note any different use of angiotensinconverting enzyme inhibitors and β-blockers, suggesting similar access to health care at least to this extent.
The differences in disease severity and prognosis are so profound that they suggest a potential difference based on genetics. Approximately 10% of patients with PPCM have truncating genetic variants in the gene TTN, encoding for the critical sarcomeric protein titin.
7 These variants were found in both African American and non-African American women, indicating that the observed clinical differences are unlikely to be explained by different burdens of mutations in TTN. The findings suggest, instead, that other propensity genetic or epigenetic modifiers exist in the African American population, such as common polymorphisms that associate with severity of outcome and are more prevalent in the African American population.
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Limitations
This study is not without limitations. As a retrospective review of medical records, not all demographic and clinical variables could be captured. Furthermore, some of the patients with PPCM were referred from outside hospitals, possibly introducing some bias. However, because the referral population contains relatively few African American patients and because referrals likely represent patients with more severe disease, we suspect that removal of this bias would, if anything, strengthen our findings. We were also unable to capture details of symptom severity. Finally, 7 women whose race was unknown were analyzed as nonAfrican American, which could represent misclassification; however, if some of these women were African American, this misclassification would have biased us away from detecting the differences observed.
Conclusions
This retrospective review of 220 patients demonstrates that African American women with PPCM fare markedly worse than non-African American patients. These women are diagnosed later post partum, they present with more severe systolic dysfunction, their cardiac function worsens after diagnosis twice as often, their cardiac function ultimately recovers half as often, and, when cardiac function recovers, it does so in at least twice as much time as in non-African American patients with PPCM. Therefore, African American patients with PPCM, at the very least, need to be counseled differently than non-African American patients. Future studies will be needed to determine whether these differences are primarily genetic or socioeconomic in origin and whether personalized therapeutic approaches could benefit these patients. 
